Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CEA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CEA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CEA antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of cancer.
|
CAR Construction : CEA scFv-TM28-CD28-CD3ζ
Fig.4 CD8+ T cells were transduced with the retroviral constructs and GFP+ CD8+ T cells (upper panel) or GFP+ Myc+ T cells gated on GFP+ CD8+ populations were analyzed by flow cytometry In vitro generation of carcinoembryonic antigen (CEA) chimeric antigen receptor T (CAR-T) cells. Fan, Jiaqiao, et al. "Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors." Frontiers in Oncology 10 (2021): 574860. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : CEA scFv-TM28-CD28-CD3ζ
Fig.5 The packaging Plat-E cells (upper panel) and MFG-transduced CD8+ T cells (lower panel) were visualized by fluorescence microscope. scale bars: 200 mm Fan, Jiaqiao, et al. "Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors." Frontiers in Oncology 10 (2021): 574860. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : CEA scFv-TM28-CD28-CD3ζ
Fig.6 GFP+ CD8+ T cells were sorted, and the cell lysates were determined for the expression of Bcl-xL and b-actin by western blotting. All data are representative of three independent experiments. Fan, Jiaqiao, et al. "Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors." Frontiers in Oncology 10 (2021): 574860. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : CEA scFv-TM28-CD28-CD3ζ
Fig.7 Carcinoembryonic antigen (CEA) chimeric antigen receptor T (CAR-T) cells overexpressing Bcl-xL had modest in vitro cytotoxicity. Representatives of the in vitro co-culture of T cells with MC-32 tumor cells at 12 h (scale bars: 50 mm). Fan, Jiaqiao, et al. "Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors." Frontiers in Oncology 10 (2021): 574860. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : CEA scFv-TM28-CD28-CD3ζ
Fig.8 Representatives of the CD8+ Thy1.2+ T cells in the LNs and spleen on day 14. All data are representative of three independent experiments. Fan, Jiaqiao, et al. "Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors." Frontiers in Oncology 10 (2021): 574860. Distributed under Open Access license CC BY 4.0, without modification. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CEA (hMN14) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP041). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
